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In this phase II, multicentre trial, patients with metastatic breast cancer (MBC) were treated with a combination of gemcitabine,
epirubicin and paclitaxel (GET). The primary objective of this study was to determine the tolerability and activity in terms of complete
responce (CR) and overall response rate of the GET combination in this patient population. Patients with no prior treatment for
MBC, and at least one bidimensionally measurable lesion received gemcitabine 1000mgm
 2 intravenously (i.v.) over 30min on days
1 and 4, followed by epirubicin i.v. at 90mgm
 2 on day 1, and paclitaxel 175mgm
 2 over 3h on day 1, every 21 days, up to eight
courses. From May 1999 to June 2000, 48 patients were enrolled from seven Italian institutions. A total of 297 chemotherapy courses
were administered with a median of six cycles patient
 1 (range 1–8). Seven patients (15%) obtained CR and 27 patients (56%) had
partial responce, for an overall response rate of 71% (95% CI: 58.3–83.7). After a median follow-up of 23.7 months (range 7.0–34.4),
median progression-free survival was 10.5 months (95% CI: 9.2–11.7), and median overall survival 25.9 months. The main
haematological toxicity consisted of grade 3 or 4 neutropenia that occurred in 62% of cycles (22% grade 4 and 40% grade 3). The
GET combination is active and well tolerated as first-line chemotherapy for MBC.
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In the past 30 years, the diagnosis and treatment of breast cancer
have advanced considerably. Systemic chemotherapy is one of the
main options of treatment for patients with metastatic breast
cancer (MBC). In these patients, combination cytotoxic regimens
were shown to achieve higher response rates, and longer duration
of response and survival compared to single-agent therapy
(Hortobagyi, 1997, 2000). However, these regimens could not
change the course of the disease. In the past decade, several newer
cytotoxic drugs, including gemcitabine, vinorelbine and the
taxanes have been developed. Combinations of these newer drugs
with older agents provide enhanced activity with a more
favourable toxicity profile for the treatment of patients with MBC.
Traditionally anthracycline-based chemotherapy resulted in
higher overall response rates compared with nonanthracycline-
containing regimens, with improvements in time to progression
and overall survival (Fossati et al, 1988; A’Hern et al, 1993). In
MBC, epirubicin-based chemotherapies are as effective as adria-
micin-containing regimens in terms of efficacy with reduced
toxicity (French Epirubicin Study Group 1988), and higher
epirubicin doses (450mgm
 2) correlate with response rate but
not with survival (Focan et al, 1993; Marschner et al, 1994; Bastholt
et al, 1996; Brufman et al, 1997; The French Epirubicin Study
Group 2000). When anthracyclines are combined with taxanes in
phase II trials evaluating activity and toxicity in MBC, the results
have shown that this combination is very active, with overall
response rates ranging from 75 to 95%, and with complete
response rates as high as 40% (Gianni et al, 1995; Gehl et al, 1996;
Conte et al, 1997; Sledge et al, 2003). More recently, six phase III
randomised trials compared anthracycline–taxane combinations
with standard anthracycline–alkylator regimens (Nabholtz et al,
1999; Luck et al, 2000; Carmichael, 2001; Jassem et al, 2001;
Biganzoli et al, 2002; Mackey et al, 2002).
Only one trial demonstrated a survival advantage for the taxane-
containing regimens (Jassem et al, 2001), but importantly, the
complete response rates in all these trials were lower than
expected. Based on these data, we have evaluated the possibility
of increasing the activity of anthracycline–taxane combinations by
adding a third active drug.
Gemcitabine seemed to be a good candidate because of its low
myelotoxicity, favourable tolerability profile, new mechanism of
action and interesting single-agent activity. The data from phase II
trials show that single-agent gemcitabine produces an objective
response rate of 25–46% in MBC; moreover, gemcitabine has a
mild toxicity profile with a low incidence of myelotoxicity and
nonhaematologic toxicity (Carmichael et al, 1995; Blackstein et al,
1996; Aapro et al, 1998). When administered in association with
taxanes in pretreated MBC patients, gemcitabine has shown an
overall response rate ranging from 41 to 51% (Rothenberg et al,
1998; Mavroudis et al, 1999). A previous single-institution phase II
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ltrial evaluated the activity and tolerability of the gemcitabine–
epirubicin–paclitaxel (GET) combination as first-line chemother-
apy in 36 MBC patients. In this trial, gemcitabine was given at
1000mgm
 2 on days 1 and 4, plus epirubicin 90mgm
 2 on day 1
and paclitaxel 175mgm
 2 for 3h infusion on day 1, every 21 days.
This study showed that the addition of gemcitabine to the
epirubicin–paclitaxel combination is well tolerated with an overall
response rate of 92% and a complete response rate of 31% (Conte
et al, 2001). In order to validate these data in a larger, multicentre
trial, we designed this phase II study to evaluate toxicity profile
and activity in terms of overall response rate and complete
response (CR) rate of the GET combination as first-line
chemotherapy in MBC patients.
PATIENTS AND METHODS
Eligibility criteria
Patients with histologically confirmed diagnosis of stage IV breast
cancer with evidence of progressive disease (PD), and at least one
bidimensionally measurable lesion, were enrolled in the trial.
Other eligibility criteria included: age between 18 and 70 years;
World Health Organization performance status (WHO-PS) o2;
adequate bone marrow reserve (white blood cell (WBC) count
44.0 10
9l
 1, neutrophils 42.0 10
9l
 1, platelets
4100 10
9l
 1, haemoglobin 4100gl
 1), adequate function for
liver (bilirubin o1.2mgdl
 1) and kidneys (creatinine concentra-
tion o1.5gdl
 1); normal left ventricular ejection fraction by
echocardiography or scintigrafy; estimated life expectancy of at
least 12 weeks. No prior chemotherapy for metastatic disease was
allowed, but adjuvant treatment, without taxanes, was permitted if
stopped at least 6 months before study entry. Adjuvant anthracy-
cline-based therapy was allowed if the total cumulative dose was
no more than 240mgm
 2 in case of doxorubicin, 360mgm
 2 in
case of epirubicin, and terminated at least 12 months before study
entry. Prior endocrine therapy was allowed. No radiation therapy
during the preceding 4 weeks was allowed. Exclusion criteria
included: central nervous system metastasis, bone metastases as
the only site of disease, previous radiation therapy on target
lesions, calcium 411mgdl
 1, active infection, pregnancy, breast
feeding, history of other cancer, use of any investigational agent in
the month before enrollment into the study, previous high-dose
chemotherapy with autologous stem cell rescue. Written informed
consent was obtained from each patient before entering the study.
The study was conducted under the approval of the appropriate
ethical review boards and the guidelines for good clinical practice.
Recommendations of the Declaration of Helsinki for biomedical
research involving human subjects were also followed. This study
did not include any patient from previous trials.
Treatment plan
This was a single arm, multicentre, phase II study of a combination
of GET as first-line therapy in patients with MBC. Gemcitabine
1000mgm
 2 was administered intravenously (i.v.) over 30min on
days 1 and 4. On day 1, gemcitabine was followed by 90mgm
 2 of
epirubicin given as i.v. bolus and 175mgm
 2 of paclitaxel
administered via i.v. over 3h. Chemotherapy was administered
in the outpatient setting, and the cycles were repeated every 3
weeks for a maximum of eight courses. All patients were
premedicated with dexamethasone, orphenadrine and cimetidine
prior to paclitaxel administration.
Dose adjustments for each subsequent cycle were based on the
toxicity observed in the previous cycle. Day 1 doses in subsequent
cycles for all three drugs were reduced by 25% in case of febrile
neutropenia requiring hospitalisation, grade 4 neutropenia lasting
more than 7 days or thrombocytopenia with bleeding. Day 4 dose
of gemcitabine was reduced by 50% in case of grade 2 neutropenia
or grade 2 thrombocytopenia, and was omitted in case of grade 3
neutropenia or grade 3/4 thrombocytopenia. Doses held due to
toxicity or missed were not given at a later time. Treatment was
stopped earlier in case of PD, patient refusal or unacceptable
toxicity.
Baseline and on-study evaluation
Baseline evaluations included medical history, physical examina-
tion with tumour measurements, WHO performance status
evaluation, chest X-ray, complete blood cell count (CBC), liver
and kidney function tests, ECG and ecocardiography with L-VEF
determination. Staging procedures appropriate to define the extent
of metastatic disease, which included computed tomography (CT)
and/or resonance imaging studies of the chest, abdomen and
pelvis, ultrasounds of liver, bone scans and radiographs of
suspicious bone segments were performed in all patients.
Complete blood cell count was obtained on days 1 and 4 and
subsequently weekly. Blood chemistry and physical examination
were performed at the start of each cycle. Toxic effects were
assessed according to the WHO Toxicity Criteria (Common
Toxicity Criteria 1993). Patients were evaluated for response
according to the World Heath Organization (WHO) criteria (Miller
et al, 1981) after every two courses of treatment. Responses were
evaluated by the same assessment methods used to determine the
disease status at baseline. A CR was defined as the disappearance
of all known disease for at least 4 weeks; a partial response (PR)
was defined as at least a 50% decrease in the sum of the products of
biperpendicular measurements of all measurable lesions. To be
assigned a status of CR or PR, changes in tumour measurements
were confirmed by repeat assessments no less than 4 weeks after
the criteria for response were first met. Stable disease (SD) was less
than 25% change in measurable lesions and no new lesions. Any
increase in measurable lesions greater than 25% or the appearance
of new metastatic sites was defined as disease progression. In the
case of bone metastases, the criteria for CR included clear evidence
of complete bone recalcification on X-ray, accompanied by either
normalisation of a previously abnormal bone scan or attainment of
a near normal architecture of the involved bone lesions on X-ray.
After the last course of chemotherapy, patients were followed up
every 3 months until death, to monitor progression and survival.
Statistical analysis
Duration of progression-free survival (PFS) and overall survival
was calculated from day 1 of the first drug administration to the
first evidence of progression or death, by the Kaplan–-Meier
method (Fleming, 1982). From a previous experience of epirubicin
plus paclitaxel, the CR rate achieved was 18%. To test an increase
in CR rate with this combination from 18 to 30%, the sample size
required was 82 patients with an alpha error¼0.1 and 1-beta
error¼0.7.
RESULTS
Patient characteristics
From May 1999 to June 2000, a total of 48 patients with MBC and
measurable disease were enrolled from seven Italian institutions.
The accrual was stopped at this point because on the basis of the
observed activity, the probability to obtain a CR rate of 30% was
very unlikely. The main patient characteristics are reported in
Table 1. The median age was 50 years (range 40–68) and the
median WHO-PS was 0 (range 0–2). Hormonal receptor status was
positive in 29 (61%), negative in 14 (29%) and unknown in five
(10%) patients. In total, 14 patients (29%) had at least three
metastatic sites, and 34 patients (71%) had dominant visceral
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ldisease. A tota lof 24 patients (50%) had received prior adjuvant
chemotherapy, including anthracyclines in three cases; and 18
patients (38%) had received prior adjuvant hormonal therapy. Five
patients (10%) had failed hormonal therapy for metastatic disease.
Response to therapy
A total of 297 chemotherapy courses were administered with a
median of six cycles patient
 1 (range 1–8). After chemotherapy,
seven patients (15%) obtained a CR and 27 patients (56%) had a
PR, for an overall response rate of 71% (95% CI: 58.3–83.7). Nine
patients (19%) achieved stable disease, while three patients (6%)
progressed during chemotherapy. Two patients (4%) could not be
evaluated due to refusal to continue the treatment after the first
course of therapy (Table 2). With a median follow-up of 23.7
months (range 7.0–34.4), median PFS was 10.5 months (95% CI:
9.2–11.7), and median overall survival was 25.9 months (Figure 1).
Toxicity
Toxicity was monitored in all 297 chemotherapy courses. Table 3
reports the most significant toxicities encountered with this
combination. The main haematological toxicity consisted of grade
3 or 4 neutropenia that occurred in 62% of chemotherapy cycles
(22% grade 4 and 40% grade 3). Dose delays or reductions were
necessary in 13% of the courses. Three episodes of febrile
neutropenia were observed. Other haematological toxicities were
uncommon: grade 3–4 anaemia and grade 3–4 thrombocytopenia
occurred in 2 and 4% of the courses, respectively.
Nonhaematological toxicity was mostly grade 1 and 2. Grade 2
neurotoxicity occurred in only three patients (6%). Grade 3 and 4
mucositis occurred, respectively, in 12 (25%) and three (6%)
patients. Grade 3 nausea/vomiting was observed in one (2%)
patient. All patients experienced complete alopecia. One episode of
grade 3 cardiac toxicity was observed in a patient pretreated with
adjuvant anthracycline; this patient experienced a decline in L-VEF
of 25%.
DISCUSSION
This multicentre phase II trial shows that the addition of
gemcitabine to the epirubicin–paclitaxel combination is well
tolerated as first-line chemotherapy in MBC patients and feasible
on an outpatient basis. Previous phase II trials of the anthracy-
cline–paclitaxel combination in MBC have reported overall
response rates of 83–94%, including CR rates up to 41% (Gianni
et al, 1995; Gehl et al, 1996; Conte et al, 1997; Sledge et al, 1997).
More recently, randomised phase III trials comparing anthracy-
cline–taxane combinations with anthracycline–alkylator regimens
showed that anthracycline–taxane regimens significantly increase
overall response rate, but CR rates remain lower than 20%
(Nabholtz et al, 1999; Luck et al, 2000; Carmichael, 2001; Jassem
et al, 2001; Biganzoli et al, 2002; Mackey et al, 2002). In our earlier
phase II monocentre study, the GET combination yielded a 92%
response rate, including 31% CR (Conte et al, 2001). Based on
these data, we designed this multicentre phase II study in order to
confirm the feasibility, tolerability and activity of this combina-
Table 1 Main patient characteristics
Characteristics No of patients (%)
Total eligible 48
Age (years)
Median 50
Range 40–68
WHO-PS
0 41 (85)
1–2 7 (15)
Hormonal receptor status
Positive 29 (61)
Negative 14 (29)
Unknown 5 (10)
Dominant metastatic site
Viscera 34 (71)
Soft tissue 14 (29)
Bone metastases 23 (48)
Number of metastatic sites
1 11 (23)
2 23 (48)
3 14 (29)
Previous therapies
Adjuvant chemotherapy (All) 24 (50)
Adjuvant anthracyclin 5 (10)
Adjuvant hormonotherapy 18 (38)
Prior hormonotherapy for metastatic disease 5 (10)
Table 2 Response rates
No of patients (%)
Complete response 7 (15)
Partial response 27 (56)
Overall response rate 34 (71)
Stable disease 9 (19)
Progressive disease 3 (6)
Not evaluated 2 (4)
0 4 8 12 16 20 24 28 32
0
10
20
30
40
50
60
70
80
90
100
P
r
o
b
a
b
i
l
i
t
y
 
 
%
Median follow-up=23.7 months
Entered=48
Progressed=43
Died=24
PFS median 10.5 months (IC 95%: 9.2-1)
OS median 25.9 months
Months
Figure 1 Progression-free survival and overall survival.
Table 3 Haematological and nonhaematological toxicity (% of cycles)
Grade 3 Grade 4
Neutropenia 40 22
Anaemia 2 —
Thrombocytopenia 3 1
Nausea/vomiting 2 —
Mucositis 25 6
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ltion. In our previous experience, median PFS was 21 months and,
with a median follow-up of 25 months, median survival was not
reached (Conte et al, 2001). In the present study, the overall
response rate achieved was 71% with 15% CR, PFS was 10.5
months and median survival was 25.9 months. Myelosuppression
was the most common adverse event, with grade 3–4 neutropenia
occurring in 40 and 22% of the courses, respectively. However,
neutropenia was reversible and did not require the support of
prophylactic G-CSF. Toxicity data from phase III trials comparing
anthracycline–taxane combinations with anthracycline–alkylator
regimens also indicated that neutropenia is the main haematologic
toxicity, but the addition of gemcitabine did not cause increased
toxicities. Most notably the incidence of febrile neutropenia was
significantly lower (6%) than that observed with other anthracy-
cline/taxane containing triplets utilised both in metastatic and
adjuvant setting. In fact, a phase III trial comparing the docetaxel/
doxorubicin/cyclophosphamide (TAC) combination to FAC as
first-line chemotherapy in MBC patients showed a high incidence
of febrile neutropenia (29%) and infection (5%) in the TAC arm
(Mackey et al, 2002), and the same combination utilized in an
adjuvant setting produced comparable toxicities with 24% of
patients experiencing febrile neutropenia (Nabholtz et al, 2002).
The activity we have observed in this multicentre phase II trial is
lower than that reported in the original, single-institution trial in
terms of CR rate, progression-free and overall survival. It is well
recognised that trials conducted in a multiinstitutional setting
produce inferior results as a consequence of differences in patient
selection criteria and management. In fact, a multicentre phase II
trial of doxorubicin plus paclitaxel conducted by ECOG showed
significantly lower overall and complete response rates (29%) in
comparison to the original report with the same drug combination
(Sparano et al, 1999).
In conclusion, the GET combination is feasible, well tolerated
and active; further studies are needed to clarify the role of this
combination in early stage breast cancer.
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